Markets

US stocks stage Herculean comeback to finish positive

US stocks started the session battered by a double whammy of negative economic news and concerns about AI demand.

At their lows of the morning, the S&P 500 and Nasdaq 100 were each down more than 2%. But stocks managed to hurdle those challenges over the course of the day and accelerated into the close, perhaps buoyed by month-end rebalancing activity.

When the dust settled, the S&P 500 and Nasdaq 100 ended in positive territory, while the Russell 2000 had a 0.6% decline.

It’s the biggest intraday loss the benchmark US stock index has erased to finish positive since October 13, 2022. That’s the day the bull market began.

Most S&P 500 sector ETFs rose, with healthcare, consumer staples, and industrials leading the way up. Energy was the massive laggard, tumbling 2.7%.

Some of the big gainers included Seagate, Trane, and Western Digital, all on earnings, which have generally surprised to the upside in a big way so far this reporting period.

But there were also some negative reports of note:

Norwegian Cruise Line shares sank after the cruise operator missed first-quarter estimates, as both ticket sales and onboard spending cooled.

Etsy shares slid nearly 6%, even after the craft-based online marketplace posted solid Q1 revenue, but swung to a loss after taking on charges from the sale of its instrument marketplace, Reverb.

Shares of Oddity Tech surged 30% after the AI-savvy beauty company delivered a standout Q1, easily topping expectations and skirting tariff fears.

Snap shares tumbled — despite beating analyst expectations yesterday — after the social media app warned that de minimis shipping changes may already be hurting its advertising business.

Shares of First Solar, the largest US manufacturer of solar panels and modules, fell about 8% after the company said it expects to pay up to $90 million in tariffs this year.

Starbucks slumped after posting a revenue and earnings miss along with a larger decline in same-store sales than analysts had penciled in.

Super Micro was the biggest sore spot on a sunny day, falling double digits after it released quarterly results that fell far short of expectations.

Shares of Jeep maker Stellantis and luxury giant Mercedes-Benz slipped after both automakers pulled their full-year guidance, citing volatility in trade policy.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.